Advanced search
Publication Cover
Leukemia & Lymphoma Volume 43, 2002 - Issue 2
Submit an article Journal homepage
100
Views
9
CrossRef citations to date
0
Altmetric
Research Article

Intermediate-dose Cytarabine Treatment Delivered at Moderate Infusion Rates for De Novo Acute Myeloid Leukemia-Results of a phase I-II Study

Luisa Mantovani Division of Medical Oncology and Hematology, Department of Internal Medicine I, St. Georg's Hospital, Delitzscher str. 141, Leipzig 04129, Germany
,
Dirk Hasenclever Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany
,
Rainer Krahl Division of Hematology and Oncology, Department of Internal Medicine II, University of Leipzig, Leipzig, Germany
,
Wolfram Pönisch Division of Hematology and Oncology, Department of Internal Medicine II, University of Leipzig, Leipzig, Germany
,
Michael Herold Division of Hematology and Oncology, Klinikum Erfurt, Germany
,
Rita Pasold Division of Hematology and Oncology, Klinikum"Ernst von Bergmann", Potsdam, Germany
,
Friedrich Fiedler Department of Internal Medicine III, Hospital Küchwald, Chemnitz, Germany
,
Gottfried Dölken Division of Hematology and Oncology, University of Greifswald, Greifswald, Germany
,
Dietrich Kämpfe Division of Hematology and Oncology, Hospital of Lüdenscheid, Lüdenscheid, Germany
,
Hans Joachim Schmoll Division of Hematology and Oncology, University of Halle/Saale, Halle/Saale, Germany
,
Rita Súbert Division of Hematology and Oncology, Klinikum Schwerin, Germany
,
Martin Kubel Division of Hematology and Oncology, Department of Internal Medicine II, University of Leipzig, Leipzig, Germany
,
Dietger Niederwieser Division of Hematology and Oncology, Department of Internal Medicine II, University of Leipzig, Leipzig, Germany
&
Werner Helbig Division of Hematology and Oncology, Department of Internal Medicine II, University of Leipzig, Leipzig, Germany
 show all
Pages 265-274 | Published online: 01 Jul 2009

  • Stone, R.M. and Majer, R.J. (1993) "Treatment of the newly diagnosed adult with de novo acute myeloid leukemia", Hematology/Oncology Clinics of North America 7, 47.
  • Weinstein, H. J., Mayer, R.J., Rosenthal, D.S., Coral, F.S., carnitta, B. M. and Gelber, R.D. (1983) "Chemotherapy for acute myelogenous leukemia in children and adults", Blood 62, 315.
  • Mayer, R.J. (1987) "Current chemotherapeutic treatment approaches to the management of previsouly untreated adults with de novo acute myelogenous leukemia", Seminars in Oncology 14, 384.
  • Preisler, H., Davis, R.B., Kishner, J., Dupre, E., Richards, F., Hoagland, H.C., Kopel, S., Levy, R. N., Carey, R., Schulman, P., Gottlieb, A.J. and McIntyre, O.R. (1987) "Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: A Cancer and Leukemia Group B study", Blood 69, 1441.
  • Vogler, W.R., Velez-Garcia, E., Weiner, R.S., Flaum, M.A., Bartolucci, A. A., Omura, G.A., Gerber, M.C. and Banks, P.L. (1992) "A Phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study Groups study", Journal of Clinical Oncology 10, 1103.
  • Bishop, J.F., Matthews, J.P., Young, G.A., Szer, J., Gillett, A., Joshua, D., Bradstock, K., Enno, A., Wolf, M.M., Fox, R., Coberoft, R., Herrmann, R., Van.Der Weyden.M., Lowenthal, R.M., Page, F., Garson, O.M. and Huneja, S. (1996) "A randomized study of high-dose cytarabine in induction in acute myeloid leukemia", Blood 87, 1710.
  • Bishop, J.F., Matthews, J.P., Young, G.A., Bradstock, K. and Lowenthal, R.M. (1998) "Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and update results of the Australian Leukemia Study Group", Leukemia and Lymphoma 28, 315.
  • Mayer, R.J., Davis, R.B., Schiffer, C.A., Berg, D.T., Powell, B.L., Schulman, P., Omura, G.A., Moore, J.O., McIntyre, O.R. and Frei, III, E. (1994) "Intensive post-remission chemotherapy in adults with acute myeliod leukemia", New England Journal of Medicine 6(14), 331-896.
  • Weick, J.K., Kopecky, K.J., Appelbaum, F.R., Head, D.R., Kingsbury, L.L., Blacerzak, S.P., Bickers, J.N., Hynes, H.E., Welborn, J.L., Simon, S.R. and Grever, M. (1996) "A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group Study", Blood 88, 2841.
  • Herzig, R.H., Wolff, S.N., Lazarus,. H.M., Phillips, G.L., Roessmann. D. and Fishman, J. (1983) "High-dose cytosine arabinoside therapy for refractory leukemia", Blood 62, 361.
  • Riva, C.M., Rustum, Y.M. and Preisler, H.D. (1985) "Pharmacokinetics and cellular determinants of response to 1-beta-arabinofuranosyl-cytosine (Ara-C)", Seminars in Oncology 12(Suppl.3), 1.
  • Plunkett, W., Liliemark, J.O., Adams, T.M., Nowak, B., Estey, E., Kantarjian, H. and Keating, M.J. (1987) "Saturation of 1-beta-arabinofuranosylcytosine 5'- triphosphate accumulation in leukemia cells during high-dose 1-beta-arabinofuranosylcytosine therapy", Cancer Research 47, 3005.
  • Plunkett, W., Liliemark, J.O., Estey, E. and Keating M.J. (1987) "Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-c", Seminars in Oncology 14, 159.
  • Hiddeman, W., Schleyer, E., Unterhalt, M., Zühlsdorf, M., Rofl, K., Reuter, C., Kewer, U., Uhrmeister, C., Wörmann, B. and Büchner, T. (1992) "Differences in the intracellular pharmacokinetics of cytosine arabinoside (ara-C) between circulating leukernic blasts and normal mononuclear blood cells", Leukemia 6, 1273.
  • Braess, J., Berkovioc, D., Feuring-Buske, M., Fleer E., Pfoertner, J., Wegendt, C., Keve, S., Riggert J., Kern, W., Unterhalt, M., Hiddemann, W. and Schleyer, E. (1998) "Ara-C metabolism in fresh leukemic blasts/normal bone marrow/hematopoetic stem cells and its impact on the lipid composition of leukemic cell (HL60)". In: Hiddemann, W., Buüchner, T., Wörmann, B., Ritter J., Creutzing, U., Keating, M. and plunkett W., eds. Acute Leukeminas VII-Experimental Approaches and Novel Therapies (Springer, Berlin/Heidelberg), p 596.
  • Phillips, G.L., Reece, D.E., Shepherd, J.D., Barnett, M.J., Brown, R.A., Frei-Lahr, D.A., Klingemann, H.G., Bolwell, B.J., Spinelli, J.J., Herzig, R.H. and Herzig, G.P. (1991) "High-dose cytarabine and daunorubicin induction and post remission chemotherapy for the treatment of acute myelogenous leukemia in adults", Blood 77, 1429.
  • Wolff, S.N., Marion, J., Stein, R.S., Flexner, J.M., Lazarus, H.M., Spitzer, T.R., Phillips, G.L., Herzig, R.H. and Herzig, G.P. (1985) "High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukernia in first remission: a pilot study", Blood 65, 1407.
  • Schiller, G.J., Nimer, S.D., Territo, M.C., Ho, W.G., Champlin, R.E. and Gajewski, J.L. (1992) "Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission", Journal of Clinical Oncology 10, 41.
  • Baer, M.R., Christiansen, N.P., Frankel, S.R., Brunetto, L., Mròzek, K., Bloomfield, C.D. and Herzig, G.P. (1993) "High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia", Seminars in Oncology 20, 6.
  • Kantarjian, H.M., Estey, E.H., Plunkett, Keating, M.J., Walters, R.S., Iacoboni, S., McCredie, K.B. and Freireich, E.J. (1986) "Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia", American Journal of Medicine 81, 387.
  • Schiller, G., Gajewski, J., Territo, M., Nimer, S., Lee, M., Belin, T. and Champlin, R., (1992) "Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia", Blood 80, 2977.
  • Hiddemann, W., Aul, C., Maschmeyer, G., Schonrock-Nabulsi, R., Ludwig, W.D., Bartholomaus, A., Bettelheim, P., Becker, K., Balleisen, L., Lathan, B., Koeppler, H., Grueneisen, T., Donhuijsen-Ant, R., Reichle. A., Heinecke, A., Sauerland, C. and Büchner, T.H. (1993) "High-dose versus interrnediate-dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison", Leukemia and Lymphoma 10, 133.
  • Büchner, T., Hiddemann, W., Wörmann, B., Loeffler, H., Maschmeyer, G., Hossfeld, D., Ludwig, W.D., Nowrousian, M., Aul, C., Schaefer, U.W., Sauerland, C. and Heinecke, A. (1992) "Longterm effects of prolonged maintenance and of very early intensification chemotherapy in AML: data from AMLCF", Leukemia 6(Suppl.2), 68.
  • Rohatiner, A., Slevin, M.L., Dhaliwal, H.S., Malpas, J.S. and Lister Tal (1984) "High-dose cytosine arabinoside: response to therapy in acute leukaemia and non-Hodgkin's lymphoma", Cancer Chemotherapy and Pharmacology 12, 90.
  • Estey, E., Keating, M.J., Plunkett, W., McCredie, K.B. and Freireich, E.L. (1987) "Continuous-infusion high-dose cytosine arabinoside without anthracyclines as induction and intensification therapy in adults under age 50 with newly diagnosed acute myelogenous leukemia", Seminars in Oncology 141(Suppl. 1), 58.
  • Ghaddar, H.M., Plunkett, W., Kantarjian, H.M., Pierce, S., Freireich, E.J., Keating, M.J. and Estey, E.H. (1994) "Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside", Leukemia 8, 1269.
  • Lee, J.H., Lee, K.H., Kim, S., Seol, M., Kim, S.H., Kim, W.K. and Lee, J.S. (2001) "Combination chemotherapy of intermediate-dose cytarabine, idarubicin, plus etoposide and subsequent mobilized donor leukocyte infusion for relapsed acute leukemia after allogenic bone marrow transplantation", Leukemia Research 4, 305.
  • Bahng, H., Lee, J.H., Ahn, J.H., Lee, J.H., Lee, J.S., Kim, S.H., Kim, W.K. and Lee, K.H. (2001) "Combination chemotherapy utilizing continuous infusion of intermediate-dose cytarabine for refractory or recurrent acute myeloid leukemia", Leukemia Research 3, 213.
  • Sternberg, D.W., Aird, W., Neuberg, D., Thompson, L., MacNeill, K., Amrein, P. and Shulman, L.N. (2000) "Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharamacologically based regimen", Cancer 9, 2037.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.